FDA expands use of cervical cancer vaccine up to age 45
Share
Tweet
October 5, 2018
U.S. regulators Friday expanded the use of Merck's cervical cancer vaccine to adults up to age 45.
The vaccine was previously only for preteens and young adults through 26. The Food and Drug Administration approved Gardasil 9 for women and men through 45.
The vaccine protects against the human papilloma virus — or HPV — which can cause cervical cancer, certain other cancers and genital warts. The virus is very common and is spread through sex. In most cases, HPV doesn't cause any problems, but some infections persist and eventually lead to cancer.
The Centers for Disease Control and Prevention...
For access to this article please
sign in or
subscribe.
Reader Comments(0)